Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
NOX-A12 (olaptesed pegol) binds to CXCL12 and inhibits its interaction with CXCR4 and CXCR7, potentially resulting in increased sensitivity to chemotherapeutic agents, as well as increased infiltration of T-cells into tumors and enhanced anti-tumor immune response in combination with other agents (PMID: 24277076, PMID: 28963140).
|CAS Registry Number||1390628-22-4|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bendamustine + NOX-A12 + Rituximab||Bendamustine NOX-A12 Rituximab||0||0|
|Bevacizumab + NOX-A12||Bevacizumab NOX-A12||0||1|
|Nilotinib + NOX-A12||NOX-A12 Nilotinib||0||0|
|NOX-A12 + Pembrolizumab||NOX-A12 Pembrolizumab||0||0|
|NOX-A12 + unspecified PD-1 antibody||NOX-A12 unspecified PD-1 antibody||0||0|